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Open access undea b s t r a c t
Ethnopharmacological relevance: Jatropha isabellei Mu¨ll Arg. (Euphorbiaceae) is a medicinal plant that
has been used in South American folk medicine for the treatment of arthritic diseases, particularly gout.
Aim of the study: This study was designed to verify the antinociceptive, anti-inﬂammatory and
hypouricemic potential of Jatropha isabellei.
Materials and methods: Rats were orally administered with the crude extract (100–300 mg/kg) or a
fraction that is rich in alkaloids (0.15 mg/kg) of Jatropha isabellei. An intra-articular (i.a.) injection of
50 ml of monosodium urate (MSU) crystals (1.25 mg/site) was used to generate the gout model to assess
the effect of the treatment on nociception (thermal and mechanical hyperalgesia) and inﬂammation
(oedema and neutrophil inﬁltration). The effect of Jatropha isabellei on the serum levels of uric acid was
evaluated in a model of hyperuricaemia induced by the intraperitoneal injection of potassium oxonate
(250 mg/kg). The side effects were analysed using an open-ﬁeld test, gastric lesion assessment and by
measuring the levels of the ALT and AST enzymes.
Results: Our study demonstrated that the crude extract of Jatropha isabellei and a fraction rich in
alkaloids were able to prevent the thermal hyperalgesia, mechanical allodynia, oedema and neutrophil
inﬁltration induced by intra-articular MSU injection in rats. On the other hand, treatment with Jatropha
isabellei did not alter the uric acid levels increased by potassium oxonate in the hyperuricaemia model.
In addition, Jatropha isabellei did not induce gastric lesions or liver damage and did not alter
spontaneous locomotor activity.
Conclusion: The crude extract of Jatropha isabellei and its fraction rich in alkaloid presents antinoci-
ceptive and anti-inﬂammatory effects in a rat gout model, similar to that observed after treatment with
colchicine, supporting the traditional use of this plant in gouty patients.
& 2012 Elsevier Ireland Ltd. Open access under the Elsevier OA license. 1. Introduction
Gout is a metabolic disorder associated with an excess of
circulating uric acid resulting in the deposition of monosodiumica, Universidade Federal de
bi, Santa Maria, RS, Brazil.
rma´cia Industrial, Universi-
Bairro Camobi, Santa Maria,
248.
Athayde),
r the Elsevier OA license. urate crystals (MSU) in tissues. This hyperuricaemia can occur via
uric acid under-excretion or overproduction, and can be readily
determined in most patients. A number of reversible factors
contribute to increased urate production, including a high-
purine diet, obesity and regular alcohol consumption (Bieber
and Terkeltaub, 2004; Choi et al., 2004). After formation, the
MSU crystals may be deposited in joints, usually in the big toe or
ankle, causing neutrophil inﬁltration, swelling and excruciating
pain (Desaulniers et al., 2001). Estimations from the Third
National Health and Nutrition Examination Survey (NHANES III)
indicate that 0.5% of the total population has suffered from a gout
attack. In addition, gout is currently considered to be the most
common form of inﬂammatory arthritis in men over 40 years old,
C.R. Silva et al. / Journal of Ethnopharmacology 145 (2013) 205–213206exceeding rheumatoid arthritis (Lawrence et al., 1998; Weaver,
2008).
The options for the treatment of chronic gout are allopurinol,
which is an inhibitor of the xanthine oxidase enzyme, probene-
cide, which is a uricosuric drug that stimulates the renal excretion
of uric acid, and non-steroidal anti-inﬂammatory drugs (NSAIDs),
such as indomethacin, that inhibit COX enzyme activity
(Cronstein and Terkeltaub, 2006; Terkeltaub, 2010). Another drug
that has been used to treat gout attacks is colchicine, which is an
alkaloid derived from the autumn crocus Colchicum autumnale
(Roberge et al., 1993). However, approximately 50% of patients
are noncompliant with the prescribed medication, especially if
they are having recurring gout ﬂares (Gaffo and Saag, 2010).
Moreover, each of these agents is associated with risks, poten-
tially severe adverse effects and drug–drug interactions. Thus,
many gout patients end up opting for treatments based on folk
medicine (Terkeltaub, 2010).
In South American folk medicine, such as Paraguayan and
Brazilian traditional medicine, dried slices of the rhizome of
Jatropha isabellei Mu¨ll Arg. (Euphorbiaceae) are empiricaly used
as an infusion or decoction to treat different types of arthritis,
especially gout (Basualdo et al., 1995; Pertino et al., 2007).
However, until now, there are not scientiﬁc pre-clinical studies
supporting the traditional use of this plant in gouty patients,
neither as analgesic-anti-inﬂammatory on attacks of gout nor as
lowering the increased serum levels of uric acid. Thus, the aim of
this work was to conﬁrm the popular use of this plant by
assessing the antinociceptive, anti-inﬂammatory and hypourice-
mic effects of the crude extract and of a fraction rich in alkaloids
obtained from Jatropha isabellei in animal models of acute attack
of gout and hyperuricaemia.2. Materials and methods
2.1. Animals
The present study was conducted in accordance with the
internationally accepted principles for laboratory animal use
and care, and all procedures were approved by our Institutional
Ethics Committee (process number 94/2010). The number of
animals and nociceptive stimuli used were the minimum neces-
sary to demonstrate the consistent effects of drugs treatments.
The behavioural evaluation was performed blindly with respect to
drug administration. All experiments were performed using adult
male Wistar rats weighing 250–300 g. The animals were housed
under a controlled temperature (2271 1C) on a 12 h light/12 h
dark cycle with standard lab chow and water ad libitum. The
animals were acclimated to the experimental room for at least 1 h
before the experiments.
2.2. Drugs and reagents
Synthetic monosodium urate (MSU) crystals were prepared as
described previously (Hoffmeister et al., 2011). Brieﬂy, 4 g of uricTable 1
Substances characterised by TLC technique.
Mobile phase
Acetone: ammonium hydroxide (97:3)
Chloroform: ethanol ammonium hydroxide (93:6.5:0.5)acid (Vetec, Brazil) was dissolved and heated in 800 mL of H2O
adjusted to pH 8.9 with NaOH (9 mL, 0.5 N) at 60 1C, cooled
overnight in a cold room and then washed and dried. The needle-
like crystals were recovered and suspended in phosphate-
buffered solution (PBS, 10.71 mM K2HPO4, 6.78 mM NaH2PO4,
120.4 mM NaCl; pH 7.4). Polarised light microscopy was used to
conﬁrm that the crystals were rod-shaped and varied in length
(1272 mm). The preparation was endotoxin-free, as determined
by an amebocyte cell lysate assay (Sigma, St Louis, MO, USA).
The crude extract of Jatropha isabellei and the fraction rich in
alkaloids were prepared in dimethylsulphoxide (DMSO, 5%),
polyethylene glycol (PEG, 20%) and PBS, 75% for oral administra-
tion (p.o.). Allopurinol and colchicine were purchased from Sigma
(USA), dissolved in PBS and administrated by oral route. Potassium
oxonate was purchased from Sigma (USA) and administrated
intraperitoneally (i.p.). In addition, 5-(N,N-diethylamino)-pentyl-
3,4,5-trimethoxybenzoate (TMB), hexadecyltrimethylammonium
bromide (HTAB), xanthine oxidase (XO) from bovine milk and
pterine were purchased from Sigma (USA).
Dragendorff’s reagent was prepared by dissolving 8 g of
bismuth subnitrate in 20 mL of nitric acid 30% (v/v). This solution
precipitated approximately 22.8 g of potassium iodide, which was
solubilised in a small amount of distilled water. The volume was
adjusted to 100 mL and ﬁltered.
Ethyl alcohol, acetone, chloroform, ammonium hydroxide and
ethyl ether were purchased from Vetec (Brazil). The Silica Gel 60
F254 coated plates used for thin layer chromatography (TLC) were
purchased from Merck (Darmstadt, Germany).
2.3. Plant collection and extraction
To prepare the plant material for animal treatment, the under-
ground parts of Jatropha isabellei Mu¨ll Arg. were collected in
Cacequi (Rio Grande do Sul, Brazil, coordinates: latitude 2915300100
south and longitude 541 4903000 west) in May of 2008. A exsiccate
was archived as a voucher specimen in the herbarium of the
Biology Department at UFSM (SMDB 11816). The underground
plant parts were dried at room temperature and powdered in a
knife mill. The powder was macerated with ethanol (70%) for ten
days at room temperature. After ﬁltration, the extract was
evaporated under reduced pressure to remove the solvent using
a rotary evaporator, resulting in crude extract. This procedure was
repeated seven times, and the extracts were combined.
2.4. Alkaloid extraction
The crude extract of Jatropha isabellei was resuspended in
hydrochloric acid (2 N) and washed with ethyl ether three times.
The aqueous fraction resulting from the partition was alkalised
with ammonium hydroxide and washed again with ethyl ether
three times. The ethereal fraction was dried, resulting in a
puriﬁed fraction of alkaloids.
The residue from the extraction of alkaloids was dissolved in
ethanol and investigated by chromatography. A quantity of 2 mL
was placed on plates and eluted with acetone:ammoniumCharacteristic Rf
254 nm: orange stain 0.82
365 nm: blue ﬂuorescent stain 0.18
365 nm: yellow ﬂuorescent 0.12
254 nm: orange stain 0.59
365 nm: blue ﬂuorescent stain 0.17
365 nm: yellow ﬂuorescent stain 0.14
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(93:6.5:0.5). The plates were observed under UV light (254 and
365 nm) and sprayed with Dragendorff’s reagent. According
Wagner et al. (2006), blue and yellow ﬂuorescent stains in
365 nm as well as orange stains in 254 nm and after sprayed
with Dragendorff’s reagent, are positive results to alkaloids. So,
the thin layer chromatography showed the presence of at least
three types of alkaloids classes (Table 1).
2.5. Estimation of alkaloids precipitable with Dragendorff’s reagent
To evaluate the amount of alkaloids precipitable with Dragen-
dorff’s reagent, we used the spectrophotometric method
described by Sreevidya and Mehrotra (2003). This method is
based on the formation of a yellow bismuth complex in a nitric
acid medium with thiourea that corresponds to the amount of
alkaloids present in the plant. Brieﬂy, 2 g of the crude extract
were solubilised in ethanol and hydrochloric acid (1%) to a
concentration of 60 mg/mL, and the pH was maintained at
2–2.5. The extract solution (5 mL) was added to 2 mL of Dragen-
dorff’s reagent, and the precipitate that formed was centrifuged
(2400 rpm for 30 min). The residue was washed with ethanol
then treated with 2 mL of disodium sulﬁde solution. The
brownish-black precipitate that formed was then centrifuged
and dissolved in 2 mL of concentrated nitric acid. This solution
was diluted to 10 mL in a standard ﬂask with distilled water. A 3%
thiourea solution (5 mL) was added to 1 mL of this solution. The
absorbance was measured at 435 nm against a blank containing
nitric acid and thiourea. The quantiﬁcation procedure showed the
percentage of alkaloids to be 0.048%. The amount of alkaloids
present was calculated by the absorbance of the sample and the
calibration curve (y¼2.2783xþ0.0361, r¼0.9996). The crude
extract of the underground parts of Jatropha isabellei showed
and alkaloid content of 0.048%.
2.6. MSU crystals-induced arthritic gout
To investigate the possible antinociceptive effect of Jatropha
isabellei, we used the arthritic gout model induced by intra-
articular injections of MSU according to the method described
by Coderre and Wall (1987), with some modiﬁcations. Brieﬂy, we
injected 50 mL of vehicle (PBS) or MSU suspension (1.25 mg/site)
to the tibio–tarsal joint (ankle) on isoﬂurane anesthetised ani-
mals. Separate groups of animals received oral administrations of
vehicle (PBS), colchicine (30 mg/kg, used as a positive control
according Chang, 1975), Jatropha isabellei crude extract (100–
300 mg/kg) or a fraction rich in alkaloids (0.15 mg/kg) 1 h before
the crystal injections. The doses of Jatropha isabellei were chosen
in pilot experiments and the maximum dose was determined by
its maximum solubility. The oedema and nociceptive parameters
were observed until ﬁnishing the antioedematogenic and anti-
nociceptive effects of the crude extract of Jatropha isabellei. For
the group treated with the fraction rich in alkaloids the para-
meters were tested at 2 h after the MSU injections only, because
at this time we can observe either antinociceptive effects on
mechanical and thermal hyperalgesia as antioedematogenic
effects. Myeloperoxidase (MPO) activity was analysed in the ankle
tissue 6 h after the crystal injection.
2.7. Nociceptive parameters
2.7.1. Mechanical hyperalgesia
The measurement of the mechanical paw withdrawal thresh-
old (PWT) was carried out using the Up-and-Down paradigm as
described previously by Chaplan et al. (1994). Brieﬂy, rats were
ﬁrst acclimatised (1–2 h) in individual clear Plexiglas boxes(9711 cm) on an elevated wire mesh platform to allow access
to the plantar surface of the hind paws. Von Frey ﬁlaments of
increasing stiffness (6–100 g) were applied to the rat hind paw
plantar surface with enough pressure to bend the ﬁlament. The
absence of paw lifting after 3 s led to the use of the next ﬁlament
with increasing stiffness, and paw lifting indicated a positive
response and led to the use of the next weakest ﬁlament. This
paradigm continued until a total of six measurements were taken
or until four consecutive positive or four consecutive negative
responses had occurred. The 50% mechanical PWT response was
then calculated from the resulting scores as described previously
by Dixon (1980). The PWT is expressed in grams (g) and was
evaluated before and several times after the i.a. injection of MSU.
A signiﬁcant decrease in PWT compared to baseline values was
considered as mechanical hyperalgesia.
2.7.2. Thermal hyperalgesia
To measure the paw withdrawal latency (PWL) to radiant heat,
the rats were placed on a glass plate surrounded by a clear plastic
chamber (Hargreaves et al., 1988). A radiant heat stimulus was
applied with a high-intensity projector lamp bulb (60 W) under-
neath the glass ﬂoor, and the withdrawal latency was measured
using an electronic timer. The heat stimulus was focused on the
plantar surface of each hind paw. The intensity of the heat
stimulus was adjusted to obtain an average baseline of approxi-
mately 9–12 s in naive rats. A 20-s cut-off was used to prevent
tissue damage. This parameter allows for the observation of the
development of thermal hyperalgesia, indicating increased pain
sensitivity. Only rapid hind paw movements that occurred close
to the heat stimulus were counted as withdrawal responses.
When rats showed locomotion or rearing, the measurements
were stopped until the animal completely settled down.
2.8. Oedema measurement
Oedema formation was assessed as an increase in ankle
thickness (in millimeter (mm)) and was measured before and
after MSU injection using a digital calliper (Hoffmeister et al.,
2011). The results are expressed as the baseline and test value of
the ankle thickness.
2.9. Myeloperoxidase (MPO) assay
To assess the neutrophil inﬁltration in ankle tissue, 6 h after
MSU-induced gout, we evaluated the MPO activity according to
the method of Suzuki et al. (1983), with some modiﬁcations.
Vehicle (PBS), colchicine (30 mg/kg, used as a positive control),
Jatropha isabellei crude extract (300 mg/kg) or a fraction rich in
alkaloids (0.15 mg/kg) was administered 1 h before the MSU
injections. Six hours after MSU injection, the animals were
anesthetised with sodium pentobarbital (100 mg/kg, i.p.) and
perfused to avoid blood interference. The animals were then
euthanatized with CO2 and the ankle tissue samples were
collected and frosted until analysis. The samples were homoge-
nised with 20 volumes of 80 mM sodium acetate buffer (pH 5.4)
plus 0.5% HTAB and centrifuged (11,200 g at 4 1C for 20 min),
and the supernatants were collected.
For the evaluation of MPO activity, 10 mL of the supernatant
were incubated with 200 mL of acetate buffer (8 mM, pH 5.4) and
40 mL of TMB (18.4 mM) at 37 1C for 3 min. The reaction was
stopped with 30 mL of acetic acid in a cold bath, and the enzyme
activity value was assessed colorimetrically at 630 nm using a
microplate reader. The results were expressed as the percent of
leukocyte inﬁltration in comparison to vehicle intra-articular
injected animals.
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To evaluate the existence of an anti-hyperuricemic effect of
the Jatropha isabellei crude extract, we used an animal model of
hyperuricaemia induced by the uricase inhibitor potassium oxo-
nate, as described previously by Nguyen et al. (2005). Brieﬂy, rats
were treated with potassium oxonate (250 mg/kg; i.p.) 1 h before
the oral administration of vehicle, Jatropha isabellei crude extract
(300 mg/kg) or the xanthine oxidase inhibitor allopurinol (10 mg/
kg, used as a positive control, Nguyen et al., 2005). Blood samples
were taken 2 h after the drug administration’s (Nguyen et al.,
2005) via capillarity from the right eye of anesthetised (90 mg/kg
of ketamine plus 3 mg/kg of xylazine hydrochloride, i.p.) rats. The
serum was obtained by centrifuging the blood samples for 10 min
at 1000 g. The levels of uric acid, urea, and creatinine in the
serum were measured using a commercial kit. The results were
expressed in mg/dL, and allopurinol was used as the positive
control.
2.11. Xanthine oxidase assay
This method was realized according Angel et al. (1986) and
Liu et al. (2008), with same modiﬁcations. Xanthine oxidase
(0.5 U/ml) was incubated with pterine (20 mM) in the presence
and absence of allopurinol (10 mg/mL) or Jatropha isabellei crude
extract (10–300 mg/mL) at 37 1C for 30 min. Then, the samples
were boiled in a water bath at 100 1C for 3 min and centrifuged at
10,000 g for 10 min. The supernatant was diluted in sodium
acetate buffer (0.1 M, pH 5.5), and the xanthine oxidase activityBaseline 1 2 4 6 24
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Fig. 1. The effect of the oral administration of the crude extract of Jatropha isabellei or colc
The time course (A) and (C) and dose–response curves (B) and (D) of the antinociceptiv
obtained 2 h after MSU injections. Each column represent the meanþ standard errors of
and Colchicine/MSU; n¼7 for Jatropha Isabellei 100 and 200 mg/kg and n¼8 for Jatro
represent signiﬁcant differences compared to the baseline level, and nPo0.05; nnPo0.01
group. The statistical analysis was performed using a one-way ANOVA followed by the St
post-hoc test (A) and (C).was determined by ﬂuorescence at 347 nm for excitation and
405 nm for emission using a spectroﬂuorometer.2.12. Assessment of side effects
2.12.1. Open-ﬁeld test
The effect of the Jatropha isabellei crude extract (300 mg/kg) or
the fraction rich in alkaloids (0.15 mg/kg) on spontaneous loco-
motor activity and exploratory behaviour was assessed using the
open-ﬁeld test as previously reported by Sauzem et al. (2009). The
locomotor activity after drug treatment was compared to the
vehicle-treated group. The apparatus was a round arena (57 cm in
diameter) with the ﬂoor divided into 21 equal areas. The number
of areas crossed with all paws and the number of rearing
responses were recorded for 5 min beginning 2 h after MSU
injections.2.12.2. Gastric lesion assessment
To evaluate the gastric tolerability of animals after the oral
administration of the Jatropha isabellei crude extract (300 mg/kg),
the fraction rich in alkaloids (0.15 mg/kg) or sodium diclofenac
(50 mg/kg, used as a positive control), the animals were treated
and euthanized 6 h after the treatments. The stomachs were
removed, opened by cutting along the greater curvature and
washed with saline at 4 1C. The lesion index was immediately
assessed using a magnifying glass. The length (mm) of each lesion
was measured, and the lesion index is expressed as the sum of the
length of all lesions (Pertino et al., 2007).Baseline Vehicle 100 200 300 30
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The activities of alanine aminotransferase (ALT) and aspartate
aminotransferase (AST) are sensitive indicators of liver, muscle
and kidney injury. To biochemically evaluate the occurrence of
toxicity, vehicle (PBS), Jatropha isabellei crude extract (300 mg/kg)
or the fraction rich in alkaloids (0.15 mg/kg) were administered.
Six hours after treatment, the animals were euthanized in a CO2
chamber, and the serum levels of ALT and AST were assessed
spectrophotometrically according to the standard procedures
provided with the commercially available diagnostic kits (BioClin
diagnostics Quibasa Quı´mica Ba´sica Ltd., Belo Horizonte, Brazil).Baseline 1 2 4 6 24
4
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)2.13. Statistical analysis
All values are expressed as the mean7S.E.M., except for the
ED50 values (the dose required to elicit 50% of the response
relative to the control value) and the ID50 values (the dose
required to elicit 50% of the prevention response relative to the
control value), which are given as geometric means accompanied
by their respective 95% conﬁdence limits and calculated for the
maximal developed responses obtained after the injection of MSU
in comparison with vehicle-treated animals. The statistical sig-
niﬁcance between groups was assessed by Student’s t-test or a
one- or two-way analysis of variance (ANOVA) when appropriate.
Post-hoc tests (Student-Newman–Keuls’-SNK for a one-way
ANOVA or Bonferroni’s test for a two-way ANOVA) were also
carried out when appropriate. P values lower than 0.05 (Po0.05)
were considered to be indicative of signiﬁcance. The ED50 and
ID50 values were determined by non-linear regression analysis
with a sigmoid dose–response equation using the GraphPad
Software 5.0 (Graph Pad, USA).Baseline Vehicle 100 200 300 30
4
J. isabellei (mg/kg) Colchicine
   (mg/kg)
MSU (1.25 mg/site)
Fig. 2. The effect of the oral administration of the crude extract of Jatropha isabellei
or colchicine on the ankle oedema induced by an intra-articular MSU injection
(1.25 mg/site). The time course (A) and dose–response curve (B) of the antioede-
matogenic effect of the crude extract of Jatropha isabellei. Each column represent
the meanþ standard errors of the mean (A) n¼7 to all groups; (B) n¼9 to
baseline, vehicle/MSU and Colchicine/MSU; n¼7 for Jatropha Isabellei 100 and
200 mg/kg and n¼8 for Jatropha Isabellei 300 mg/kg). Vertical lines show the SEM.
###Po0.001 represents a signiﬁcant difference compared to the basal level;
nPo0.05 and nnPo0.01 represent signiﬁcant differences compared to the vehi-
cle-treated group. The statistical analysis was performed using a two-way ANOVA
followed by Bonferroni’s test (A) and a one-way ANOVA followed by the Student-
Newman–Keuls’ test (B).3. Results
3.1. The effects of Jatropha isabellei crude extract on the nociception
and oedema induced by MSU
Animals that received an intra-articular injection of MSU
crystals (1.25 mg/site) developed mechanical hyperalgesia, char-
acterised by a signiﬁcant reduction in the PWT when the von Frey
ﬁlaments were applied to the injected ankle from 1 up to 24 h
(Fig. 1A). The Jatropha isabellei crude extract (300 mg/kg, p.o.)
prevented the mechanical hyperalgesia induced by MSU from 1 to
6 h after administration, with a complete reversal at 2 h (Fig. 1A).
The PWT diminished from 22.677.1 g at baseline to 6.873.7 g
two hours after the MSU injection, and treatment with the
Jatropha isabellei crude extract (300 mg/kg) prevented this PWT
decrease (15.474 g) (Fig. 1B). The lower doses of crude extract
(100 or 200 mg/kg) did not alter the MSU-induced mechanical
hyperalgesia (Fig. 1B). The ED50 value (and the 95% conﬁdence
limits) calculated for the crude extract of Jatropha isabellei anti-
nociception was 217 (176–268) mg/kg (Fig. 1B).
Likewise, we also observed the development of thermal
hyperalgesia after an intra-articular injection of MSU crystals,
indicated by the decrease in the PWL from 2 to 4 h when the
injected paw was exposed to radiant heat (PWL diminished from
12.875 s at baseline to 6.873 s at two hours, and 7.273 s at
four hours after MSU injection; Po0.001, Fig. 1C). The treatment
with the Jatropha isabellei crude extract (200 or 300 mg/kg)
partially reduced (68720% of prevention with 300 mg/kg) the
thermal hyperalgesia observed 2 h after MSU injection (Fig. 1D).
The ED50 value (and the 95% conﬁdence limits) calculated for the
antinociceptive effect of the crude extract of Jatropha isabellei was
102 mg/kg (Fig. 1D).Similar to the Jatropha isabellei crude extract, the alkaloid
colchicine (30 mg/kg, p.o., used as a positive control) inhibited
both the mechanical and thermal hyperalgesia caused by MSU
with 74721% and 79714% of prevention, respectively (Fig. 1B
and D).
The animals that received an intra-articular injection of MSU
crystals (1.25 mg/site) showed an increase in ankle thickness,
indicating the development of an oedema that was sustained
from 1 to 24 h after MSU injection (ankle thickness increased
from 5.670.9 mm at baseline to 7.770.6 mm 2 h after MSU
injection; Po0.001, Fig. 2B). It was observed that the Jatropha
isabellei crude extract (300 mg/kg, p.o.) was able to partially
prevent oedema formation at 2 and 4 h after MSU injection, with
3578 and 2473% of prevention, respectively. The lower doses of
crude extract (100 or 200 mg/kg) did not alter the MSU-induced
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Fig. 3. The effect of the oral administration of the crude extract of Jatropha isabellei
or colchicine on the neutrophil inﬁltration induced by an intra-articular MSU
injection (1.25 mg/site) analysed 6 h after the MSU injections. Each column
represent the meanþ standard errors of the mean (n¼9 to all groups). Vertical
lines show the SEM. ###Po0.001 represents a signiﬁcant difference compared to
the vehicle injected group; nPo0.05 and nnPo0.01 represent signiﬁcant differ-
ences compared to the MSU injected group. The statistical analysis was performed
using a one-way ANOVA followed by the Student-Newman–Keuls’ test.
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Fig. 4. The effect of the oral administration of the crude extract of Jatropha isabellei or
allopurinol on the uric acid (A), urea (B) and creatinine (C) serum levels induced by
potassium oxonate (250mg/kg, i.p.). The samples were obtained 2 h after potassium
oxonate treatment. Each column represent the meanþ standard errors of the mean
(A)–(C) n¼6 to all groups). Vertical lines show the SEM. ##Po0.01 represents a
signiﬁcant difference compared to the basal levels, and nnPo0.01 represents a
signiﬁcant difference compared to the vehicle-treated group. The statistical analysis
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lated for the antioedematogenic effect of the crude extract of
Jatropha isabellei was 223 (149–336) mg/kg (Fig. 2B). The treat-
ment with colchicine (30 mg/kg) prevented oedema formation
(44714%) 2 h after the MSU injections.
Furthermore, the Jatropha isabellei crude extract (300 mg/kg) did
not alter PWT, PWL or ankle thickness when orally administered to
animals that received intra-articular injections of vehicle, demon-
strating no effect of the crude extract alone (data no shown).
Because only the dose of 300 mg/kg (p.o.) was able to prevent the
nociceptive and oedematogenic effects induced by MSU injection,
this dose was chosen for the remaining experiments.
3.2. The effects of Jatropha isabellei crude extract on the neutrophil
inﬁltration induced by MSU
To investigate if treatment with Jatropha isabellei alters neu-
trophil inﬁltration, we assess the neutrophil inﬁltration in articu-
lar tissue after MSU injection by analysing the MPO activity
(Fig. 3). We do not observe MPO activity at 2 or 4 h after MSU
injection (data not shown). We observed that the MSU crystals
induced cellular inﬁltration in the ankle articulation when com-
pared with the control group (animals that received intra-
articular injections of vehicle). The increase in MPO activity was
fully prevented by both the Jatropha isabellei crude extract and
colchicine administration (80720% and 95725% prevention,
respectively).
3.3. The effects of Jatropha isabellei crude extract on potassium
oxonate-induced hyperuricaemia in rats
To evaluate the existence of a hypouricemic effect of the
Jatropha isabellei crude extract, we used a model of hyperuricaemia
in rats. As shown in Fig. 4, the injection of potassium oxonate
(250 mg/kg, i.p.) markedly increased the serum uric acid levels
compared with the control group (Fig. 4A). Treatment with the
xanthine oxidase inhibitor allopurinol (10 mg/kg, p.o., used as a
positive control) signiﬁcantly prevented the uric acid increase in
potassium oxonate-treated animals (89710% prevention), while
the Jatropha isabellei crude extract treatment did not alter the uricacid levels (Fig. 4A). We did not observe any differences in the
serum levels of urea or creatinine among the groups (Fig. 4B and C).
In addition, only the high concentration of the Jatropha isabellei
was performed using a one-way ANOVA followed by the Student-Newman–Keuls’ test.
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xantine oxidase activity in vitro. Allopurinol (10 mg/ml), the positive
control, inhibited xantine oxidase activity by 5472% (Fig. 5).
3.4. The effects of a fraction rich in alkaloids extracted from Jatropha
isabellei on the nociception and articular oedema induced by MSU
intra-articular injection
We hypothesised that the antinociceptive and anti-inﬂammatory
effects demonstrated by the Jatropha isabellei crude extract could beVehicle 10 10 100 300
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Fig. 5. The effect of different concentrations of the crude extract of Jatropha
isabellei or allopurinol on xanthine oxidase activity in vitro. nPo0.05 represents a
signiﬁcant difference compared to vehicle. The statistical analysis was performed
using a one-way ANOVA followed by the Student-Newman–Keuls’ test.
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Fig. 6. The effect of the oral administration of a fraction rich in alkaloids extracted from
MSU injections (1.25 mg/site). The antinociceptive effects of the fraction rich in alkaloid
inﬂammatory effects of the fraction rich in alkaloids observed in ankle oedema form
hyperalgesia and oedema formation were analysed two hours after the MSU injections.
represent the meanþ standard errors of the mean (A)–(C), n¼4 for vehicle/vehicle; n¼
SEM. #Po0,05, ##Po0,01 and ###Po0,001 represent signiﬁcant differences compar
compared to the MSU intra-articular injected and vehicle-treated group. The statistica
(A)–(C) or a one-way ANOVA followed by the Student-Newman–Keuls’ test (D).partially due to the presence of alkaloids in the plant. To test this,
we veriﬁed the antinociceptive and the anti-inﬂammatory effects of
a fraction rich in alkaloids extracted from Jatropha isabellei. Similar
to the results obtained for the crude extract, we observed that the
fraction rich in alkaloids (0.15 mg/kg, p.o., a dose equivalent to the
alkaloid content in the crude extract of Jatropha isabellei) was able to
prevent the mechanical hyperalgesia (83712% prevention), thermal
hyperalgesia (4376% prevention), articular oedema (61711% pre-
vention) and neutrophil inﬁltration (7079% prevention) induced by
MSU at 2 h after its administration (Fig. 6).3.5. Assessment of the side effects of Jatropha isabellei treatment
3.5.1. The effects of Jatropha isabellei on the open-ﬁeld test
Treatment with the crude extract (300 mg/kg) or the fraction
rich in alkaloids (0.15 mg/kg) obtained from Jatropha isabellei
caused no change in the locomotor coordination activity com-
pared with the vehicle treated animals, as evaluated by both the
total number of crossings and rearings in the open-ﬁeld test after
treatment (Table 2).3.5.2. Gastric lesion assessment
Treatment with the crude extract or the fraction rich in
alkaloids obtained from Jatropha isabellei (300 mg/kg) did not
induce gastric lesions. As expected, the positive control, sodium
diclofenac, induced gastric lesions in the stomach mucosa of the
rats (Table 2).0
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Jatropha isabellei on the nociception and inﬂammation induced by intra-articular
s observed in mechanical hyperalgesia (A) and thermal hyperalgesia (B). The anti-
ation (C) and MPO enzyme activity (D). The mechanical hyperalgesia, thermal
The MPO activity was determined six hours after the MSU injections. Each column
7 for vehicle/MSU and alkaloid/MSU; D n¼5 to all groups). Vertical lines show the
ed to baseline levels; nPo0,05 and nnPo0,01 represent signiﬁcant differences
l analysis was performed using a two-way ANOVA followed by Bonferroni’s test
Table 2
The assessment of side effects after Jatropha isabellei treatment.
Groups (mg/kg) Number of crossing/rearing Gastric lesion index AST/ALT activity (U/L)
Naı¨ve 4978/2373 0 290720/112718
Vehicle 5176/2574 0 30572/117722
Sodium diclofenac (50 mg/kg) ND 1173 ND
Jatropha isabellei crude extract (300 mg/kg) 3978/2373 0 346732/114712
Jatropha isabellei Fraction rich in alkaloids 4277/2073 ND 244731/9279
(0.15 mg/kg)
ND¼not determined.
C.R. Silva et al. / Journal of Ethnopharmacology 145 (2013) 205–2132123.5.3. Liver damage
Treatment with the crude extract or the fraction rich in
alkaloids obtained from Jatropha isabellei (300 mg/kg) caused no
change in AST or ALT enzyme activity when compared with the
vehicle treated animals (Table 2).4. Discussion
Gout is a hyperuricemic condition associated with the deposi-
tion of sodium urate crystals in the joints, leading to neutrophil
inﬁltration and consequent swelling and pain (Martinon, 2010).
The management of gout has changed relatively little in the past
50 years, despite the fact that many gout patients have contra-
indications to one or more of the currently available gout
therapies. In South American traditional medicine, Jatropha isa-
bellei is often used in the treatment of arthritic diseases, especially
gout (Pertino et al., 2007). Our study demonstrated that Jatropha
isabellei was able to prevent the nociception, oedema formation
and neutrophil inﬁltration produced by an injection of MSU
crystals in rats, conﬁrming its traditional use. Moreover, we
suggest that these effects can be attributed, in part, to the
presence of alkaloid constituents in the plant.
We ﬁrst analysed the antinociceptive and antioedematogenic
effects of the crude extract of Jatropha isabellei in a rat gout model
induced by MSU. We observed that the crude extract (300 mg/kg,
p.o.) prevented the mechanical allodynia and thermal hyperalge-
sia induced by MSU injections, and its efﬁcacy was similar to that
found for colchicine. These results clearly indicate the existence of
an analgesic-like effect of Jatropha isabellei. It is an interesting
ﬁnding because pain is the most frequent and unpleasant sign of
gout attacks (Martinon et al., 2006; Terkeltaub, 2010).
In addition to pain relief, gout treatment also must reduce the
inﬂammatory reaction induced by MSU to avoid a worsening of
the disease over time (Cronstein and Terkeltaub, 2006; Landis and
Haskard, 2001; Sabina et al., 2010). MSU crystals may stimulate
an innate immune response with the production and release of
several pro-inﬂammatory mediators, such as kinins, interleukin
and tumour necrosis factor, from the plasma and resident cells.
Some of these mediators are chemotactic and amplify the inﬂam-
matory reaction by inducing leukocyte inﬁltration, which, if left
unchecked, can lead to tissue damage (Desaulniers et al., 2001;
Cronstein and Terkeltaub, 2006; Landis and Haskard, 2001;
Sabina et al., 2010; Martinon, 2010; Popa-Nita and Naccache,
2010). Of note, treatment with the Jatropha isabellei crude extract
(300 mg/kg, p.o.) was able to not only reduce the oedema but also
prevent the neutrophil inﬁltration induced by MSU injection. This
is an important ﬁnding because the reduction of leukocyte
inﬁltration may prevent its further activation and consequent
tissue injury.
The accumulation of crystals may also be an indirect result of
hyperuricaemia. Although hyperuricemic is not a direct indicator
of gout, it has long been considered to be the most important risk
factor for the onset of gout (Osada et al., 1993; Mandell, 2008;Gaffo et al., 2009). We demonstrated that in the hyperuricemic
model, allopurinol fully prevented the uric acid increase com-
pared with the control group. However, Jatropha isabellei did not
show any effect on hyperuricaemia. These results suggest that
this plant is unable to inhibit uric acid biosynthesis. On the other
hand, we observed that only a high concentration of the Jatropha
isabellei crude extract was capable of inhibiting xanthine oxidase
activity in vitro. Thus, the antinociceptive and antioedematogenic
effects of Jatropha isabellei do not occur by xanthine oxidase
inhibition or alterations in the uric acid levels when the crude
extract was administrated. This is most likely due to a lack
characteristics of absorption or the metabolism of the compounds
responsible for the effect after oral administration in vivo. Thus,
our pre-clinical study suggests that Jatropha isabellei could be
useful to treat gout attacks, similar to colchicine or NSAID, but
does not prevent them, as is the case for allopurinol.
Colchicine is an alkaloid isolated from the seed of the autumn
crocus Colchicum and has been shown to reduce pain and
inﬂammation in patients with acute gout attacks (Ahern et al.,
1987; Richette and Bardin, 2010). Our results suggest that the
crude extract of Jatropha isabellei is acting in a way that is similar
to the alkaloid colchicine. This raises the possibility that alkaloid
constituents in Jatropha isabellei may contribute to the effects of
the crude extract. Consistent with this hypothesis, we demon-
strated that a fraction rich in alkaloids extracted from this plant
was able to prevent the nociception, oedema formation and
neutrophil inﬁltration induced by MSU crystals at a dose that
was equivalent to the alkaloid content of the crude extract. This
result indicates that the alkaloids present in Jatropha isabellei may
be responsible, at least in part, for the antinociceptive and anti-
inﬂammatory effects of this plant.
Apart its beneﬁcial effect of pain and inﬂammation, the use of
NSAIDs in arthritic patients is limited by side effects, such as
gastrointestinal lesions and renal failure (Janssens et al., 2008;
Kobata et al., 2009). We observed that oral treatment with
Jatropha isabellei did not induced gastric lesions. On the contrary,
previous studies have demonstrated that the Jatropha isabellei
crude extract is gastroprotective and has low toxicity in rats
(Pertino et al., 2007). In accordance with these ﬁndings we did not
detect any alteration in the activity of enzymes that indicated
liver or renal injury (ALT and AST, respectively) or in the
locomotor activity of rats after treatment with the Jatropha
isabellei crude extract or a fraction rich in alkaloids. Taken
together, these data indicate that the Jatropha isabellei crude
extract has low toxicity. However, further studies investigating
the toxicity of chronic treatment with this extract must be carried
out to evaluate the safety of this plant.5. Conclusions
The crude extract of Jatropha Isabellei Mu¨ll Arg. presents
antinociceptive and anti-inﬂammatory effects in a rat model
of gouty arthritis without producing a hypouricemic effect.
C.R. Silva et al. / Journal of Ethnopharmacology 145 (2013) 205–213 213These results further support the traditional use of this plant in
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